Matches in Nanopublications for { ?s ?p "[The objective of the investigation was to study the efficacy of a MEK1/2 inhibitor in thyroid cancer preclinical models with defined BRAF mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NP706253.RAdOtSxUtkADZUs61H-uzN_94oXwx3V6AjUkQpRyGlMfY130_assertion description "[The objective of the investigation was to study the efficacy of a MEK1/2 inhibitor in thyroid cancer preclinical models with defined BRAF mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP706253.RAdOtSxUtkADZUs61H-uzN_94oXwx3V6AjUkQpRyGlMfY130_provenance.
- NP645796.RA1aYCyfxAfHOarWdcykaFUgKaZZh4ukolYiPsVW9ApIc130_assertion description "[The objective of the investigation was to study the efficacy of a MEK1/2 inhibitor in thyroid cancer preclinical models with defined BRAF mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645796.RA1aYCyfxAfHOarWdcykaFUgKaZZh4ukolYiPsVW9ApIc130_provenance.
- NP630732.RAeu4UdpeIlkmB4bVnx7q-GGNHN3x3DHKp3n-Gzu0cZ2Y130_assertion description "[The objective of the investigation was to study the efficacy of a MEK1/2 inhibitor in thyroid cancer preclinical models with defined BRAF mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP630732.RAeu4UdpeIlkmB4bVnx7q-GGNHN3x3DHKp3n-Gzu0cZ2Y130_provenance.
- NP645911.RAj34PN1hzvHOfJG2jIMK3B4McCU9jErMTzJAWS6WWE_Y130_assertion description "[The objective of the investigation was to study the efficacy of a MEK1/2 inhibitor in thyroid cancer preclinical models with defined BRAF mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645911.RAj34PN1hzvHOfJG2jIMK3B4McCU9jErMTzJAWS6WWE_Y130_provenance.
- NP630723.RAguE3IqbxjwVCCj-ciRrSNS9n47B8QlbDPkvvN6LqbNQ130_assertion description "[The objective of the investigation was to study the efficacy of a MEK1/2 inhibitor in thyroid cancer preclinical models with defined BRAF mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP630723.RAguE3IqbxjwVCCj-ciRrSNS9n47B8QlbDPkvvN6LqbNQ130_provenance.